Ketamine: Dissociative Effects & Clinical Use

What Ketamine Is

Ketamine was developed as a surgical anaesthetic in the early 1960s, approved by the FDA in 1970, and has been used medically ever since — in human surgery, veterinary medicine, and emergency medicine worldwide. It is a Schedule III substance in the United States and a Schedule I substance in Canada, meaning it has accepted medical use but also recognised abuse potential.

Ketamine entered the psychedelic research space through a convergence of two streams: its long history of recreational use for dissociative experiences, and mounting clinical evidence for rapid antidepressant effects in treatment-resistant patients. Esketamine (Spravato), a nasal spray containing the S(+) enantiomer of ketamine, received FDA approval for treatment-resistant depression in 2019 — making it the first psychedelic-adjacent treatment to achieve mainstream regulatory approval.

Pharmacology: How Ketamine Works

Ketamine's primary mechanism is antagonism of NMDA (N-methyl-D-aspartate) glutamate receptors — a fundamentally different mechanism from classical psychedelics, which act primarily on serotonin 5-HT2A receptors. NMDA receptors are involved in synaptic plasticity, learning, memory, and pain processing. Blocking them produces the dissociative, anaesthetic, and psychedelic-adjacent effects characteristic of ketamine.

The antidepressant mechanism appears to operate through downstream neuroplasticity: ketamine's NMDA antagonism triggers a rapid increase in synaptic AMPA receptor activation, followed by a burst of BDNF (brain-derived neurotrophic factor) release and downstream mTOR signalling — rapidly promoting synaptogenesis (new synaptic connections) in prefrontal circuits that are compromised in depression. This explains ketamine's uniquely rapid antidepressant onset — often within hours — compared to conventional antidepressants that require weeks.

Effects

Ketamine's experiential quality is distinctive — it has more in common with dissociatives like PCP and DXM than with psilocybin or LSD. The signature phenomenon is depersonalisation-derealization: a sense of detachment from one's body, thoughts, and ordinary sense of self, often accompanied by a floating or out-of-body quality.

Low to moderate doses

Relaxation, mild dissociation, dreamy quality, perceptual distortions (particularly visual and auditory). Reduced pain sensitivity. A sense of detachment from worry and rumination that many find temporarily therapeutic.

Higher doses: the "k-hole"

At sufficiently high doses, ketamine produces a state of profound dissociation — complete detachment from the body and ordinary sense of self, with vivid internal experiences that can range from ego-dissolving and transcendent to terrifying. The "k-hole" is unpredictable and can be distressing without appropriate set, setting, and support. Recovery is typically complete within 30–60 minutes of reaching peak.

Duration

Ketamine's psychedelic effects are notably brief compared to classical psychedelics: 45–90 minutes for a moderate dose (intramuscular or intravenous), 20–40 minutes for intranasal. This brevity is clinically valuable — it allows supervised sessions without the 4–8-hour commitment required for psilocybin or LSD.

Dosage and Routes of Administration

Therapeutic protocols typically use IV or IM administration in clinical settings. Intranasal and oral formulations are used in out-of-clinic prescribing contexts. Non-therapeutic recreational use typically involves intranasal administration.

Ketamine vs. Classical Psychedelics

The differences are substantial and matter for understanding therapeutic applications and phenomenological character:

Mechanism. NMDA antagonist (ketamine) vs. 5-HT2A agonist (classical psychedelics). Different receptor systems, different neural networks affected.

Phenomenology. Dissociation, detachment, floating (ketamine) vs. perceptual richness, ecological encounters, emotional depth, ego dissolution (classical psychedelics). Ketamine experiences are generally less likely to produce the relational and ecological phenomenological content that characterises psilocybin and ayahuasca.

Duration. 45–90 minutes (ketamine) vs. 4–12 hours (classical psychedelics). Ketamine is far more clinically manageable.

Dependence potential. Meaningful (ketamine) vs. very low (classical psychedelics). This is among the most important distinctions from a harm reduction perspective.

Legal status. Medically prescribed and regulated (ketamine) vs. Schedule I (most classical psychedelics in most jurisdictions). Ketamine is currently the only route to legal, clinically administered psychedelic-adjacent treatment in most of North America.

Clinical Research on Ketamine

The clinical evidence for ketamine's antidepressant effects is substantial and replicable — arguably more robust in aggregate than psilocybin, simply because research has been ongoing since the 1990s. Multiple meta-analyses confirm rapid, significant antidepressant and anti-suicidal ideation effects in treatment-resistant patients. The challenge is durability: antidepressant effects typically last days to weeks rather than months, and repeated dosing raises tolerance and dependence concerns.

Research on whether the psychedelic experience itself contributes to antidepressant effects (beyond the neuroplasticity mechanism) is ongoing and contested. Some studies suggest the dissociative experience contributes; others suggest the biological mechanism is sufficient. This has direct implications for the role of set, setting, and integration in ketamine therapy.

Ketamine Therapy in Practice

Ketamine therapy clinics have expanded rapidly across North America. The landscape ranges from rigorous, psychotherapy-integrated protocols to medical spas that administer ketamine infusions with minimal psychological support. The quality of the container matters — the same neuroplasticity-promoting properties that make ketamine effective for depression can consolidate whatever psychological content and relational patterns are active during and after the session.

Thoughtful ketamine therapy includes: careful intake and screening; intentional preparation; supervised administration with supportive presence; immediate post-session integration; and ongoing psychotherapy between sessions. Clinics that offer IV drips with noise-cancelling headphones but no psychological preparation or integration support are providing the pharmacology without the context.

Risks: Dependence, Bladder, and Cognition

Dependence. Unlike classical psychedelics, ketamine carries genuine dependence potential — both psychological (the dissociative relief it provides can become a sought-after escape) and, with very frequent use, some degree of physical dependence. Daily or near-daily ketamine use has been documented and is associated with serious harm. This risk is primarily relevant in recreational/unmanaged use rather than structured therapeutic contexts.

Ketamine-induced uropathy. Frequent, high-dose ketamine use is associated with severe and potentially irreversible bladder damage — ketamine uropathy. Symptoms include urinary frequency, urgency, pain, and in advanced cases, reduced bladder capacity requiring surgical intervention. This risk is dose- and frequency-dependent; it has been documented primarily in recreational users taking large amounts frequently, but it is a serious harm and a meaningful reason to avoid chronic non-therapeutic use.

Cognitive effects. Heavy ketamine use is associated with impaired memory and cognitive function. Effects appear to be largely reversible with abstinence in moderate users, but may be more persistent in heavy, chronic users.

Dissociation as a risk. For people with a history of dissociative symptoms, PTSD-related derealization, or dissociative disorders, ketamine can reinforce dissociation rather than facilitate healing — without careful therapeutic framing and support.

Frequently Asked Questions